About Gap junction alpha-8 protein
Gap junction alpha-8 protein (GJA8) is a protein
from Homo sapiens identified by UniProt accession
P48165, 433 residues long.
MolForge cross-references it against 0 known binders and
297 disease associations.
Target properties
| Protein name | Gap junction alpha-8 protein |
| UniProt accession | P48165 |
| Gene | GJA8 |
| Organism | Homo sapiens |
| Length | 433 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (297)
Diseases linked to this target (Open Targets).
- Cataract-microcornea syndrome · score 0.85
- cataract · score 0.60
- Developmental cataract · score 0.55
- early-onset non-syndromic cataract · score 0.54
- pulverulent cataract · score 0.39
- genetic disorder · score 0.37
- early-onset nuclear cataract · score 0.37
- total early-onset cataract · score 0.37
- early-onset sutural cataract · score 0.37
- Isolated congenital sclerocornea · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P48165-F1 | alphafold | PREDICTED | 64.86 | — |
Amino-acid sequence (433 residues)
MGDWSFLGNI LEEVNEHSTV IGRVWLTVLF IFRILILGTA AEFVWGDEQS DFVCNTQQPG CENVCYDEAF PISHIRLWVL QIIFVSTPSL MYVGHAVHYV RMEEKRKSRE AEELGQQAGT NGGPDQGSVK KSSGSKGTKK FRLEGTLLRT YICHIIFKTL FEVGFIVGHY FLYGFRILPL YRCSRWPCPN VVDCFVSRPT EKTIFILFML SVASVSLFLN VMELGHLGLK GIRSALKRPV EQPLGEIPEK SLHSIAVSSI QKAKGYQLLE EEKIVSHYFP LTEVGMVETS PLPAKPFNQF EEKISTGPLG DLSRGYQETL PSYAQVGAQE VEGEGPPAEE GAEPEVGEKK EEAERLTTEE QEKVAVPEGE KVETPGVDKE GEKEEPQSEK VSKQGLPAEK TPSLCPELTT DDARPLSRLS KASSRARSDD LTV
Explore Gap junction alpha-8 protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets